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Background: Spinocerebellar Ataxia Type 3/Machado-Joseph Disease (SCA3/MJD) is a hereditary neurodegenerative
disorder resulting from the expansion of CAG repeats in the ATXN3 gene. It is the most common autosomal
dominant ataxia in the world, but its frequency prevalence in Cuba remains uncertain. We undertook a national study
in order to characterize the ATXN3 gene and to determine the prevalence of SCA3/MJD in Cuba.
Results: Twenty-two individuals belonging to 8 non-related families were identified as carriers of an expanded ATXN3
allele. The affected families come from the central and western region of the country. Ataxia of gait was the initial
symptom in all of the cases. The normal alleles ranged between 14 and 33 CAG repeats while the expanded ones
ranged from 63 to 77 repeats. The mean age at onset was 40 ± 9 years and significantly correlated with the number of
CAG repeats in the expanded alleles.
Conclusions: This disorder was identified as the second most common form of spinocerebellar ataxia (SCA) in Cuba
based on molecular testing, and showing a different geographical distribution from that of SCA2. This research
constitutes the first clinical and molecular characterization of Cuban SCA3 families, opening the way for the
implementation of predictive diagnosis for at risk family members.
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Spinocerebellar Ataxia Type 3 (SCA3) also known as
Machado-Joseph Disease (MJD) is a polyglutamine neu-
rodegenerative disorder caused by the expansion of a
(CAG)n in the ATXN3 gene. Normal alleles range from
11 to 44 CAG repeats, whereas pathogenic expansions
range from 61 to 87 CAGs [1].
A variety of clinical features can be observed in sub-
jects carrying ≥52 CAG units [2-4]. The first linkage
studies were facilitated by the identification of founders
with Portuguese-Azorean ancestry [5].* Correspondence: gyanetza@gmail.com; velazq63@gmail.com
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article, unless otherwise stated.SCA3 is characterized by cerebellar ataxia, ocular rota-
tory muscles palsy, gaze-evoked nystagmus, pyramidal
and extrapyramidal signs, as well as sleep disorders. The
age of onset of SCA3/MJD is variable, but most com-
monly in the second to fifth decade. Taking into consid-
eration the variability of the age at onset and clinical
manifestations, five subtypes of SCA3/MJD can be rec-
ognized [6-8].
At worldwide, the disease is the most common form
of autosomal dominant ataxia [3,9,10] and several stud-
ies have been reported [11]. Nevertheless, in Cuba there
is little information on the epidemiological, clinical and
molecular features of the SCA3. A national survey con-
ducted to establish the epidemiological profile of inher-
ited ataxias in this island identified a reduced frequencyed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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dominant cerebellar ataxias, whereas the molecular and
clinical data were not provided [12]. Moreover, the vari-
ation of the CAG repeats in the general population may
be important to predict the prevalence of chromosomes
predisposed to undergo CAG expansions and conse-
quently cases do to de novo mutations.
Therefore, a clinical and molecular genetic study of a
cohort of SCA3 families was developed to determine the
prevalence and distribution of MJD/SCA3 in the Cuba.
The normal variation of CAG repeats and their unstable
behavior were also evaluated.
Results
Epidemiological findings
Mean age of the included patients was 45.47 years
(range 14–73, Standard deviation (SD) 13.62) whereas
the mean of available ages at onset was 40.64 years
(range 13–64, SD 11.92). Age at onset was available for
18 of the 22 molecularly confirmed cases, with a mean
of 40 ± 9 years (range 21–55 years) and an inverse cor-
relation with the expanded CAG repeats (r = −0.81; p =
0.00005) (Figure 1).
The SCA3 mutation was detected in 22 out 136 indi-
viduals (16%), who belonged to 8 apparently unrelated
families (three families with two affected members, two
with four affected members, two families with one affected
member and one family with six affected members). In
these families, the genealogical information indicated the
existence of 55 affected individuals and 99 first degree
at-risk relatives. Also, the recognized genealogical origins
in two distinct families were from Portugal and Spain.
Among affected individuals, only 29 cases were still
alive in Cuba. This suggests a national SCA3 prevalenceFigure 1 Distribution of families affected by SCA3/MJD in Cuba.of 0.26 cases/100 000 inhabitants and a frequency of
4.1% among the dominant ataxias in Cuba. Analysis
of the geographic location of affected families revealed
an origin at the central-western region of the country
(Figure 2).
Clinical features in SCA3/MJD patients
All SCA3 patients showed gait ataxia as initial symptom
of the disease. Almost all of them retained gait auton-
omy with the exception of five patients (22.7%) who re-
quired external support and four (18.2%) who used a
wheelchair. Other cerebellar features were dysdiadocho-
kinesia (16 out 22, 73%), cerebellar dysarthria (15 out 22,
68%) dysmetria (15 out 22, 68%) and kinetic tremor (14
out 22, 64%). Nine patients suffered from dysphagia
(41%). Pathological nystagmus was the most important
oculomotor sign (17 out 22, 77%), followed by horizontal
saccade slowing in 7 out 22 cases (32%).
Among the non-cerebellar features, painful muscle cramps
were the most common symptoms appearing in 18 out 22
subjects (82%), followed by hypoesthesia, paresthesia or
hypopallesthesia in 13 out 22 cases (59%). Facial atrophy
was observed in nine out 22 (41%) subjects. Pyramidal fea-
tures (hyperreflexia, Babinski sign and fasciculations) were
present in three patients (10%) with more than 20 years
of disease duration. Two patients referred manifestations
of depression (9%) and fatigue was reported by one case
(4.5%). Four subjects (18%) manifested spasticity, resem-
bling a phenotype similar to hereditary spastic para-
plegia with cerebellar ataxia. Craniocervical dystonia was
present in one patient, who carried the largest CAG repeat
and earliest age at onset. Eyelid retraction was not
observed. Neither signs of Parkinsonism nor chorea were
detected.
Figure 2 Age of onset and CAG correlation: Significant inverse correlation between age of onset and expanded CAG repeats. AO: Age
at onset; CAG: Expanded CAG repeats.
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Expanded alleles varied from 63 to 77 CAG repeats (mean
69.6, SD 3.29), following a normal distribution (K-S D =
0.01; p > 0.20). The skew of the distribution was 0.03 ±
0.49. Thirteen distinct allele’s classes were detected.
Alleles with 68 CAG repeats were the most frequent (18.2%)
(Figure 3A). All expanded CAG repeats classified as alleles
with full penetrance (>52 CAG).
Up to 20 transmissions of the expanded CAG alleles
were observed (15 paternal and 5 maternal). The CAG
size of the expanded alleles in patients with paternal in-
heritance (mean 69.2, SD 3.33) and maternal inheritance
(mean 71.6, SD 4.06) were not statistically different (p =
0.420). CAG size transmission was analysed in only three
parent–child pairs; without expansions or contractions.
All control individuals carried non-expanded CAG re-
peats. Twenty allelic classes were found, ranging from
14 to 35 CAG repeats (mean: 22.0, SD 5.17) (Figure 3B).
Alleles with 23 (26.2 %) and 15 (23.8 %) CAG repeats
were the most frequent. The allele’s distribution in this
group was bimodal and not normal (K-S D = 0.17; p <
0.01), showing a negative skew (−0.007 ± 0.21).
Discussion
Spinocerebellar Ataxia Type 3 is the commonest auto-
somal dominant inherited spinocerebellar ataxia worldwide,
with variable prevalence according to ethnic background
[11]. The present paper showed the epidemiological, clinical
and molecular characterization of SCA3 in Cuba, result-
ing from the nationwide epidemiological survey for SCAs
[12]. These findings identify SCA3 as the second most
frequent molecularly confirmed autosomal dominantcerebellar ataxia in Cuba, only surpassed by SCA2, but
more prevalent than SCA7 (0.10%), and SCA1 (0.05%) [13].
The frequency of SCA3 is lower in Cuba than reported
in Brazil (72%) [14], Portugal (58%) [15], China (48%)
[16], Japan (28%), Germany (42%) and Spain (15%) [6,11],
but is similar to those in India (5%), a country with a rela-
tively higher frequency of SCA2 mutations [17]. Although
our genealogical data revealed the origin of two Cuban
kindred from populations with higher SCA3 frequencies,
further haplotype studies are needed to determine the an-
cestral origin of SCA3 mutation in the Cuban population,
since previous analyses of ATXN3 gene polymorphisms
have supported evidences of independent and multiple
origin of SCA3 in different populations [5].
Our findings confirmed the progressive, multisystemic
and pleomorphic nature of SCA3 [6]. The main clinical
features of Cuban SCA3 patients were in agreement with
previous reports. [6,7,18,19]. Pathological nystagmus is
the most frequent oculomotor alteration of SCA3 patients
[19] being present in 90% of the cases. In the present
paper we confirmed the higher frequency of this feature,
suggesting the marked involvement of cerebellar oculo-
motor circuitry in these patients, whereas the relatively
small lower frequency of saccade slowing suggests the less
involvement of pontine nuclei compared to SCA2 and
SCA7, which has been previously confirmed by neuro-
pathological findings [20].
Non-cerebellar manifestations are common features of
SCA3 patients [21], which were confirmed in the Cuban
SCA3 population. Among them, cramps were the most
prevalent, with a frequency similar to that reported by
Kanai and co-workers in 2003 [22], who identified an
Figure 3 Frequency distribution for expanded ATXN3 alleles from the 22 confirmed SCA3 patients (A) and for the unexpanded ATXN3
alleles from all patients and the 65 healthy controls (B).
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cal origin of this feature. These findings have important
implications for the management of patients due to the
intensity and frequency of cramps in SCA3. Some pa-
tients have reported improvement using carbamazepine
and mexiletine [22,23], which can be applied in Cuban
SCA3 subjects as symptomatic therapeutical options.
Other frequent non-cerebellar features observed in
this cohort were the clinical signs of peripheral neur-
opathy, which was observed as frequent as in previous
reports [24,25] and suggest the involvement of periph-
eral nervous system in SCA3, as has been confirmed
previously by neurophysiological studies [24-26]. As the
peripheral signs are characteristic for the Type III SCA3
subtype, our findings suggest the higher prevalence of
this phenotype in the Cuban population with SCA3
symptoms. Depression was the most common psychi-
atric feature in agreement with other authors [27,28].
In our cohort, the percentage of SCA3 patients exhi-
biting pyramidal signs is similar to observed by Jardim
and co-workers in 2001 [19] in a large cohort of Brazilian
SCA3 patients. Also, it is known that SCA3 patientspresent cerebellar ataxia associated spasticity, resembling
the hereditary spastic paraplegia phenotype. Wang and
co-workers identified CAG expansions in the ATXN3
gene of six Chinese subjects with hereditary spastic para-
plegias (HSP) [8]. Our findings of SCA3 Cuban patients
with a phenotype similar to hereditary spastic paraplegia
are in agreement with this report, supporting a consider-
ation to analyse the ATXN3 gene in patients clinically
diagnosed as HSP. In SCA3, dystonia is usually asso-
ciated to early onset of the disease and larger CAG ex-
pansions [14,21], which was confirmed in the present
study because the only patient exhibiting dystonia had the
largest CAG expansion and earliest age at onset, belong-
ing to the Type I SCA3 subtype [7]. Although eyelid re-
traction and signs of Parkinsonism have been observed in
SCA3 patients, these features were not observed in the
Cuban cohort.
Our data confirmed a significant correlation between
expanded CAG repeats and age at onset, demonstrating
that the expanded CAG size in the ATXN3 gene is re-
sponsible of the approximately 80% of the age at onset
variability in the patients, which suggests the existence
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SCA3 age at onset. A recent study carried out in 12
Cuban SCA3 patients demonstrated that the hyperme-
thylation of the ATXN2 gene correlated with earlier on-
set of SCA3 symptoms, which identify this epigenetic
feature as a modifying factor of SCA3 [29].
The effect of gender on the intergenerational instabil-
ity of the expanded CAG repeats was analysed. Paternal
mutant alleles are slightly more unstable than maternal
ones thus they are more prone to expand or to contract
when transmitted to the next generation [30]. Although
over one half of parent–child transmissions in the MJD
repeats are unstable [7], in our sample, CAG instability
was not detected. However, age at onset anticipation
(−11 years) was found in a parent–child transmission
without CAG repeat expansion as formerly documented
[31]. Nevertheless, further analyses in larger cohorts are
recommended.
The range of normal and expanded alleles found in
our study is similar to those reported in other popula-
tions [31,32]. Their distribution showed well established
limits between normal and expanded repetitions without
reduced penetrance alleles, making it possible to confirm
or exclude the molecular diagnosis. In accordance with
other reports, the distribution of normal alleles showed
a bimodal pattern [32,33], which is similar to that found
by Lima and co-workers in a Portuguese population
[32]. In both distributions, alleles with 23 repeats were
the most frequent.
It had been suggested that large normal alleles (>27 re-
peats) may constitute a reservoir for the emergence of
expanded alleles, since both share the same haplotypes
[33]. Although the SCA3 frequency in our study is lower
than in other studies, the observation of a frequency of
large normal alleles of 0.25 deserves further evaluation of
predisposed haplogroups. A recent study revealed that lon-
ger ATXN3 alleles were associated with earlier ages at on-
set for SCA2 in a Brazilian population of SCAs patients
[34]. As SCA2 is the most common subtype of SCAs in
Cuba this finding needs to be confirmed in the homoge-
neous population of SCA2 patients living in Cuba.
Conclusion
In conclusions, SCA3 was identified as the second most
common recognized spinocerebellar ataxia in the Cuba
showing different epidemiological characteristics to SCA2.
This research reports the first clinical and molecular
characterization of Cuban SCA3 families, providing the
knowledge necessary for the establishment of predictive
and confirmatory diagnosis and the possibility of clinical
trials for at risk family members. Haplotypes studies have
been helpful in diverse populations [35] and we plan simi-
lar studies to determine the origin of the SCA3 founder
mutation in the Cuban population.Methods
Study design
This study represents a prospective epidemiological survey
of SCA3 in the Cuban population during 2007–2013 as
part of a nationwide epidemiological study of Hereditary
Ataxias in Cuba. The study was conducted by the National
Center for the Research and Rehabilitation of the Hereditary
Ataxias in the city of Holguin (CIRAH), which is the main
referral center for these conditions in the country.
Patients
One hundred and thirty-six patients (61 female, 75 male)
affected with autosomal dominant cerebellar ataxia with-
out the abnormal expansion in the ATXN2 gene, were
tested for ATXN3 mutation in the CIRAH. Also 65 healthy
subjects (31 female; 34 male) were included as control
group. The study was approved by the Institutional Ethics
Committee. Written informed consent was obtained in
all cases.
Neurological and genealogical assessments
The neurological examination for all subjects was performed
following Mayo Clinic procedures [36], also the genea-
logical information was obtained throughout a standard-
ized interview.
Molecular genetics studies
Genomic DNA was isolated from peripheral blood leuco-
cytes using a standard protocol [37]. The ATXN3 CAG re-
peat was assessed by polymerase chain reaction (PCR)
amplification with the previously published MJD52 and
MJD25 oligonucleotide primers [38] and fragment analysis
using ReproGel™ high resolution in an ALFexpress se-
quencer (Amersham Biosciences, Sweden).
Statistical analysis
Statistical analysis was conducted using the STATISTICA
data analysis software system, version 6. StatSoft, Inc.,
2003 (www.statsoft.com). The normality of all variables
was assessed through the Kolmogorov-Smirnov (K-S) test.
Mean comparisons were performed using the Student
T-test. Correlation was assessed by the Pearson test.
Statistical significance was considered when p < 0.05.
Competing interests
The authors declare that they have no competing interests.Authors' contributions
YG-Z, LEA-M and LV-P conceived of the study, and participated in its design
and coordination. YG-Z, LEA-M, GSC, RA-R NC-O and TC-M participated in the
acquisition of data and analysis of data. YG-Z, YV-M, JML-M carried out the
molecular genetic studied and interpretation of results. YG-G, YV-M and RR-L
performed the statistical analysis and were involved in drafting the manuscript.
PM helped to draft the manuscript. TC-M, PM, JML-M and LV-P made critical
revision of the manuscript for important intellectual content. All authors read
and approved the final manuscript.
González-Zaldívar et al. Cerebellum & Ataxias  (2015) 2:1 Page 6 of 6Authors' information
L V-P, PhD. Head of Centre for the Research and Rehabilitation of Hereditary
Ataxias (CIRAH), Holguín, Cuba. Senior Academic. Cuban Academy of Science.
Awards ¨George Foster¨.
Acknowledgements
We are grateful to all patients, their families and the control individuals for
their participation, as well as to Doctors Edilberto Góngora Martínez,
Humberto Jorge Cedeño and Annelié Estupiñán Rodríguez. This work was
supported by the Cuban Ministry of Public Health and by the cooperation of
friends and family of Anselmo Amaral.
Author details
1Centre for the Research and Rehabilitation of Hereditary Ataxias (CIRAH),
Libertad Street 26, Holguín Postal code 80100, Cuba. 2Division of Medical
Genetics, Department of Pathology, Laboratory Medicine and Medical
Genetics, Victoria General Hospital, Victoria, Canada.
Received: 22 October 2014 Accepted: 12 February 2015
References
1. Whaley NR, Fujioka S, Wszolek ZK. Autosomal dominant cerebellar ataxia
type I: a review of the phenotypic and genotypic characteristics. Orphanet J
Rare Dis. 2011;28:6–33.
2. Maciel P, Costa MC, Ferro A, Rousseau M, Santos CS, Gaspar C, et al.
Improvement in the Molecular Diagnosis of Machado-Joseph Disease. Arch
Neurol. 2001;58(11):1821–7.
3. Paulson HL. Dominantly inherited ataxias: Lessons learned from
Machado–Joseph disease/spinocerebellar ataxia type 3. Semin Neurol.
2007;27(2):133–42.
4. Van Alfen N, Sinke RJ, Zwarts MJ, Gabreëls-Festen A, Praamstra P, Kremer BP,
et al. Intermediate CAG repeat lengths (53, 54) for MJD/SCA3 are associated
with an abnormal phenotype. Ann Neurol. 2001;49:805–7.
5. Martins S, Calafell F, Gaspar C, Wong VC, Silvera I, Nicholson GA, et al. Asian
origin for the worlwide-spread mutational event in Machado-Joseph
disease. Arch Neurol. 2007;64(10):1502–8.
6. Bettencourt C, Lima M. Machado-Joseph Disease: from first descriptions to
new perspectives. Orphanet J Rare Dis. 2011;6:35.
7. Paulson H. Machado-Joseph Disease/Spinocerebellar Ataxia Type 3. Handb
Clin Neurol. 2012;103:437–49.
8. Wang YG, Du J, Wang JL, Chen J, Chen C, Luo YY, et al. Six cases of SCA3/
MJD patients that mimic hereditary spastic paraplegia in clinic. J Neurol Sci.
2009;285:121–4.
9. Margolis RL. The spinocerebellar ataxias: order emerges from chaos. Curr
Neurol Neurosci Rep. 2002;2:447–56.
10. Schols L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant
cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet
Neurol. 2004;3:291–304.
11. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions
and beyond. Lancet Neurol. 2010;9:885–94.
12. Velázquez PL, Sánchez CG, Santos FN, LE Almaguer M, Escalona BK,
Rodríguez LR, et al. Molecular epidemiology of spinocerebellar ataxias in
Cuba: Insights into SCA2 founder effect in Holguín. Nuerosci Lett.
2009;454:157–60.
13. Velázquez-Pérez Luis and Rodríguez Labrada R: Early manifestations of
Spinocerebellar Ataxias type 2. Holguín: Ediciones Holguín: 2012.
14. Teive HAG, Munhoz RP, Arruda WO, Lopes-Cendes I, Raskin S, Werneck LC,
et al. Spinocerebellar ataxias- genotype-phenotype correlations in 104
Brazilian families. Clinics. 2012;67(5):443–9.
15. Vale J, Bugalho P, Silveira I, Sequeiros J, Guimaraes J, Coutinho P. Autosomal
dominant cerebellar ataxia: frequency analysis and clinical characterization
of 45 families from Portugal. Eur J Neurol. 2010;17(1):124–8.
16. Tang B, Liu C, Shen L, Dai H, Pan Q, Jing L, et al. Frequency of SCA1, SCA2,
SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in
patients with hereditary spinocerebellar ataxia from Chinese kindreds.
Arch Neurol. 2000;57(4):540–4.
17. Saleem Q, Choudhry S, Mukerji M, Bashyam L, Padma MV, Chakravarthy A,
et al. Molecular analysis of autosomal dominant hereditary ataxias in the
Indian population: high frequency of SCA2 and evidence for a common
founder mutation. Hum Genet. 2000;106(2):179–87.18. Riess O, Rü U, Pastore A, Bauer P, Schöls L. SCA3: Neurological features,
pathogenesis and animal models. The Cerebellum. 2008;7:125–37.
19. Jardim LB, Pereira ML, Silveira I, Ferro A, Sequeiros J, Giugliani R. Neurologic
findings in Machado-Joseph disease relation with disease duration, subtypes,
and (CAG)n. Arch Neurol. 2001;58:899–904.
20. Seidel K, Siswanto S, Brunt ERP, den Dunnen W, Korf H-W , Rüb U: Brain
pathology of spinocerebellar ataxias. Acta Neuropathol. 2012;124:1–21
21. Pedroso JL, Franca MC, Braga-Neto P, D’Abreu A, Saraiva-Pereira ML, Saute JA,
et al. Nonmotor and Extracerebellar Features in Machado-Joseph Disease:
A Review. Mov Disord. 2013;28:1200–8.
22. Franca Jr MC, D’Abreu A, Nucci A, Lopes-Cendes I. Muscle excitability
abnormalities in Machado-Joseph disease. Arch Neurol. 2008;65:525–9.
23. Kanai K, Kuwabara S, Arai K, Sung JY, Ogawara K, Hattori T. Muscle cramp in
Machado-Joseph disease: altered motor axonalexcitability properties and
mexiletine treatment. Brain. 2003;126:965–73.
24. van de Warrenburg BP, Notermans NC, Schelhaas HJ, van Alfen N, Sinke RJ,
Knoers NV, et al. Peripheral nerve involvement in spinocerebellar ataxias.
Arch Neurol. 2004;61:257–61.
25. Franca Jr MC, D’Abreu A, Nucci A, Cendes F, Lopes-Cendes I. Prospective
study of peripheral neuropathy in Machado-Joseph dis-ease. Muscle Nerve.
2009;40:1012–8.
26. Klockgether T, Schols L, Abele M, Bürk K, Topka H, Andres F, et al. Age
related axonal neuropathy in spinocerebellar ataxia type 3/Machado-Joseph
disease (SCA3/MJD). J Neurol Neurosurg Psychiatry. 1999;66:222–4.
27. Schmitz-Hübsch T, Coudert M, Tezenas du Montcel S, Giunti P, Labrum R,
Dürr A, et al. Depression comorbidity in spinocerebellar ataxia. Mov Disord.
2011;26:870–6.
28. Saute JA, da Silva AC, Donis KC, Vedolin L, Saraiva-Pereira ML, Jardim LB.
Depressive mood is associated with ataxic and non-ataxic neurological
dysfunction in SCA3 patients. Cerebellum. 2010;9:603–5.
29. Laffita-Mesa JM, Bauer P, Kourí V, Serrano LP, Roskams J, Gotay DA, Brown JCM,
Rodríguez PAM, González-Zaldívar Y, Mederos LA, Cuello-Almarales D,
Santiago JA: Epigenetics DNA methylation in the core ataxin-2 gene
promoter: novel physiological and pathological implications. Hum Genet
2011;131(4):625–38.
30. Costa CM, Paulson HL. Toward understanding Machado-Joseph Disease.
Prog Neurobiol. 2012;97(2):239–57.
31. Lopes-Cendes I, Teive HGA, Cardoso F, Viana EM, Calcagnotto ME, Costa JC,
et al. Molecular characteristics of Machado-Joseph disease mutation in 25
newly described Brazilian families. Braz J Genet. 1997;20:717–24.
32. Lima M, Costa MC, Montiel A, Ferro A, Santos C, Silva C, et al. Population
genetics of wild-type CAG repeats in the Machado-Joseph disease gene in
Portugal. Hum Hered. 2005;60:156–63.
33. Gan SR, Shi SS, Wu JJ, Wang N, Zhao GX, Weng ST, et al. High frecuency of
Machado-Joseph disease identified in Southeastern Chinese kindreds with
spinocerebellar ataxia. BMC Medical Genetics. 2010;11:47.
34. de Castilhos RM, Furtado GV, Gheno TC, Schaeffer P, Russo A, Barsottini O,
et al. Rede Neurogenetica. Spinocerebellar ataxias in Brazil–frequencies and
modulating effects of related genes. Cerebellum. 2014;13(1):17–28.
35. Martins S, Soon BW, Wong VCN, Giunti P, Stevanin G, Ranum LPW, et al.
Mutational origin of Machado-Joseph Disease in the Australian Aboriginal
Communities of Groote Eylandt and Yirrkala. Arch Neurol. 2012;69(6):746–51.
36. Denny-Brown D, Dawson DM, Tyler HR. Handbook of neurological
examination and case recording. 3rd ed. Cambridge, Mass: Harvard
University Press; 1982.
37. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual.
New York: Cold Spring Harbor Laboratory Press; 1989.
38. Kawaguchi Y, Okamoto T, Taniwaki M, Aizagua M, Inoue M, Katayama S,
et al. CAG expansions in a novel gene for Machado-Joseph disease at
chromosome 14q32.1. Nat Genet. 1994;8:221–8.
